NEI Research News

Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease.

Researchers from UCSB report the development of a new microscope they describe as “Dual Independent Enhanced Scan Engines for Large field-of-view Two-Photon imaging (Diesel2p),” which provides unprecedented brain-imaging ability.

CellSight researchers at the University of Colorado School of Medicine are offering the first evidence connecting drusen formation, or yellowish deposits that accumulate under the retina, with extracellular vesicles and age-related macular degeneration.

Researchers have uncovered the mechanism of vision loss in Usher syndrome, yielding additional drug targets for eventual development of better therapies.

The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.

A Northwestern Medicine study in mice has identified new treatment targets for glaucoma, including preventing a severe pediatric form of glaucoma, as well as uncovering a possible new class of therapy for the most common form of glaucoma in adults.

Damaging DNA builds up in the eyes of patients with geographic atrophy, an untreatable, poorly understood form of age-related macular degeneration that causes blindness, new research from the University of Virginia School of Medicine reveals.

By temporarily suspending retinal activity in the non-amblyopic eye of animal models, neuroscientists restrengthened the visual response in the amblyopic eye, even at ages after the critical period when patch therapy fails.

Researchers have developed a new gene therapy that could eventually provide an alternative treatment for Fuchs’ endothelial corneal dystrophy, a genetic eye disease affecting roughly one in 2,000 people globally.